Angiotensin II induces differential insulin action in rat skeletal muscle

Juthamard Surapongchai, Mujalin Prasannarong, Tepmanas Bupha-Intr and Vitoon Saengsirisuwan

Abstract

Angiotensin II (ANGII) is reportedly involved in the development of skeletal muscle insulin resistance. The present investigation evaluated the effects of two ANGII doses on the phenotypic characteristics of insulin resistance syndrome and insulin action and signaling in rat skeletal muscle. Male Sprague–Dawley rats were infused with either saline (SHAM) or ANGII at a commonly used pressor dose (100 ng/kg/min; ANGII-100) or a higher pressor dose (500 ng/kg/min; ANGII-500) via osmotic minipumps for 14 days. We demonstrated that ANGII-100-infused rats exhibited the phenotypic features of non-obese insulin resistance syndrome, including hypertension, impaired glucose tolerance and insulin resistance of glucose uptake in the soleus muscle, whereas ANGII-500-treated rats exhibited diabetes-like symptoms, such as post-prandial hyperglycemia, impaired insulin secretion and hypertriglyceridemia. At the cellular level, insulin-stimulated glucose uptake in the soleus muscle of the ANGII-100 group was 33% lower ($P<0.05$) than that in the SHAM group and was associated with increased insulin-stimulated IRS-1 Ser307 and decreased Akt Ser473 and AS160 Thr642 phosphorylation and GLUT-4 expression. However, ANGII-500 infusion did not induce skeletal muscle insulin resistance or impair insulin signaling elements as initially anticipated. Moreover, we found that insulin-stimulated glucose uptake in the ANGII-500 group was accompanied by the enhanced expression of ACE2 and MasR proteins, which are the key elements in the non-classical pathway of the renin–angiotensin system. Collectively, this study demonstrates for the first time that chronic infusion with these two pressor doses of ANGII induced differential metabolic responses at both the systemic and skeletal muscle levels.

Introduction

Insulin resistance of skeletal muscle represents a major defect in the maintenance of euglycemia and is often accompanied by a variety of metabolic and cardiovascular abnormalities, including glucose intolerance, hyperinsulinemia, hypertension, dyslipidemia, obesity and atherosclerosis. A cluster comprising these diabetic and atherogenic risk factors is known as insulin resistance syndrome (Reaven 2005, DeFronzo & Tripathy 2009). Increasing evidence indicates a link among insulin resistance, hypertension and the development of diabetes. For example, hypertensive individuals have higher fasting glucose and insulin levels than non-hypertensive
individuals, whereas patients with untreated hypertension are more likely to develop new-onset diabetes than non-hypertensive subjects (Gress et al. 2000, Bosch et al. 2006).

Angiotensin II (ANGII), a vasoactive peptide of the renin-angiotensin system (RAS), has been defined as one of the major causes of hypertension and is involved in the development of insulin resistance condition (Sower 2004, de Kloet et al. 2010, Luther & Brown 2011). In support of this, a higher level of plasma ANGII has been demonstrated to be associated with diabetic severity (Nicola et al. 2001). Clinical observation has demonstrated that patients with essential hypertension have plasma ANGII levels that are 2- to 4-fold higher than levels in healthy individuals, whereas renal hypertensive patients can demonstrate an 8-fold increase in plasma ANGII levels (Catt et al. 1969). ANGII infusion via implantable osmotic minipumps has been widely used as an experimental model to investigate the pathological processes in organs as well as disease conditions (Qin 2008). It has been reported that a more commonly used dose, 100 ng/kg/min, increased plasma ANGII levels by 2-fold, whereas a high pressor dose of ANGII infused at 500 ng/kg/min increased plasma ANGII levels by 4- to 6-fold and aggravated hypertensive conditions (Staroukine et al. 1984). Of note, studies examining the impact of ANGII infusion on insulin action have yielded inconsistent results (Ogihara et al. 2013). Therefore, we hypothesized that the extent to which ANGII modulates insulin action on glucose transport activity and related signaling elements in skeletal muscle can be affected by the dose of ANGII.

Recently, the ACE2/ANG(1–7)/MasR axis is viewed as an alternative RAS system that counters the deleterious actions of the ACE/ANGII/AT1R axis. For example, activation of the ACE2/ANG(1–7)/MasR axis improved glucose and lipid metabolism (Ferrario et al. 2005, Santos et al. 2008, 2013, Prasannarong et al. 2012a, Echeverria-Rodriguez et al. 2014, Santos & Andrade 2014). However, it remains unknown whether insulin resistance of skeletal muscle glucose transport activity induced by ANGII infusion is associated with changes in the expression of proteins in the ACE2/ANG(1–7)/MasR axis.

In light of this information, the present study was designed to test the following hypotheses: (1) ANGII induces cardiometabolic abnormalities and impairs insulin-stimulated glucose uptake in skeletal muscle in a dose-dependent fashion and (2) ANGII-induced skeletal muscle insulin resistance would be accompanied with disruptions of the insulin signaling pathway and the ACE2/ANG(1–7)/MasR axis. To address these issues, we investigated the extent to which ANGII infusion at a more commonly used dose (100 ng/kg/min; ANGII-100) and a high pressor dose (500 ng/kg/min; ANGII-500) modulate arterial pressure, glucose tolerance, serum triglyceride levels, insulin-stimulated skeletal muscle glucose transport activity, the protein expression and phosphorylation status of the signaling molecules known to be involved in the glucose transport process and the expression of key proteins in the RAS pathways in male Sprague–Dawley rats.

Materials and methods

Animal treatment

Eight-week-old male Sprague–Dawley rats, weighing between 260 and 290 g, supplied by the National Laboratory Animal Center, Thailand, were housed at the Center of Animal Facilities, Faculty of Science, Mahidol University. The housing unit was controlled at 22°C with a 12/12-h light/dark cycle (light on from 06:00 to 18:00 h), and the animals had free access to water and pellet rat chow (Perfect Companion, Samutprakarn, Thailand). The rats were randomly assigned to either a sham operation (SHAM, n=10) or chronic ANGII infusion (n=20). Subcutaneous implantation of Alzet osmotic minipumps (model 2002) (Durect Cooperation, Cupertino, CA, USA) in rats occurred on the back, slightly posterior to the scapulae. The surgery was performed under anesthesia following the company’s recommended procedure. The SHAM group was infused with normal saline. ANGII was dissolved in saline acidified with 0.01 M acetic acid to maintain its stability and was infused at a rate of 100 or 500 ng/kg/min. Body weight, food and water intake were monitored regularly during the 14-day experimental period. All animal procedures were approved by the Animal Care and Use Committee, Faculty of Science, Mahidol University, in accordance with the International Guiding Principles for Biomedical Research Involving Animals of the Council for International Organizations of Medical Sciences.

Blood pressure determination

One week before the treatment began, animals were acclimated to the tail-cuff plethysmography apparatus (CODA Monitor System, Kent Scientific Corporation, Torrington, CT, USA) by placing the animal in a holding tube with the pressure cuff at the base of the animal’s tail. The systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) and heart rate (HR)
were measured in conscious rats before implantation of osmotic minipumps and 5 and 10 days after the implantation. The mean of ten consecutive readings was used for the reported value of SBP, DBP, MAP and HR for each rat.

**Oral glucose tolerance test (OGTT)**

Following 10 days of the ANGII infusion, an oral glucose tolerance test was performed to determine insulin sensitivity at the whole body level. In the evening (18:00 h) of the day before the test, each rat was food-restricted to 4 g of chow. The next morning (08:00–09:00 h), 0.5 mL of tail blood was collected before and 15, 30, 60 and 120 min after glucose feeding (1 g/kg BW) by gavage. Blood samples were mixed with EDTA as an anticoagulant, and plasma samples were prepared. Each animal was given 2.5 mL of sterile 0.9% saline subcutaneously immediately after the test to replace fluid loss. Plasma was used to determine the levels of glucose by colorimetric assay (Gesellschaft fur Biochemica and Dianostica, Wiesbaden, Germany) and insulin by radioimmunoassay (Linco Research).

**Insulin action on skeletal muscle glucose transport activity**

The ANGII infusion continued for four days after the OGTT. All animals were food-restricted as described above. At 08:00 h, animals were weighed and anesthetized with an intraperitoneal injection of thiopental (100 mg/kg body wt). Soleus muscles were isolated and prepared for in vitro incubation. The two soleus muscles were divided into three strips each. Two non-incubated soleus strips were quickly frozen in liquid nitrogen for subsequent analyses of signaling proteins. Four fresh soleus strips (~25 mg) were incubated for 30 min at 37°C in 3 mL of oxygenated Krebs–Henseleit buffer (KHB) supplemented with 8 mM D-glucose, 32 mM D-mannitol and 0.1% radioimmunoassay-grade bovine serum albumin (Sigma Chemical, St Louis, MO, USA). Two of these four muscle strips were incubated in the absence of insulin, and the other two were incubated in the presence of a maximally effective concentration of insulin (2 mU/mL; Human R, Eli Lilly). The flasks were continuously gassed with a mixture of 95% O₂ and 5% CO₂ throughout the incubation and glucose transport assay. After the first incubation period, two of the soleus strips (one incubated without insulin and one incubated with insulin) were removed, trimmed of fat and connective tissue and quickly frozen in liquid nitrogen. These strips were subsequently used for the determination of signaling elements in response to insulin activation by immunoblotting. The remaining muscle strips were rinsed for 10 min at 37°C in 3 mL of oxygenated KHB containing 40 mM D-mannitol, 0.1% BSA and insulin, if previously present. Muscle strips were incubated for 20 min at 37°C in 2 mL of KHB containing 1 mM 2-[1,2-3H]deoxyglucose (2-DG, 300 μCi/mmol; PerkinElmer Life Sciences, Boston, MA, USA), 39 mM [U-14C]mannitol (0.8 μCi/mmol; PerkinElmer Life Sciences), 0.1% BSA and insulin, if previously present. At the end of the incubation period, the muscle strips were removed, trimmed of excess fat and connective tissue and immediately frozen in liquid nitrogen and weighed. The frozen muscles were solubilized in 0.5 mL of 0.5 N NaOH, and 10 mL of scintillation cocktail (Ultima Gold; PerkinElmer Life Sciences) was added. The specific intracellular accumulation of 2-DG was determined as described previously using mannitol to correct for the extracellular accumulation of 2-DG (Henriksen & Halseth 1994). Glucose transport activity was measured as the intracellular accumulation of 2-DG (in pmol/mg muscle wet weight/20 min).

**Tissue and blood collection**

After the removal of muscle tissues to determine glucose transport activity, blood was collected from the abdominal vein. Whole blood was allowed to clot and then centrifuged at 3000 g at 4°C for 20 min to obtain serum, which was used to determine serum triglyceride levels. Immediately after blood collection, intra-abdominal fat and the heart were collected and weighed.

**Analyses of signaling elements in skeletal muscle**

Muscles were homogenized in ice-cold lysis buffer: 50 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM CaCl₂, 1 mM MgCl₂, 2 mM EDTA, 10 mM NaF, 20 mM sodium pyrophosphate, 20 mM β-glycerophosphate, 10% glycerol, 1% Triton X-100, 2 mM Na₃VO₄, 10 μg/mL aprotinin and leupeptin, and 2 mM PMSF. After a 20-min incubation on ice, the homogenates were centrifuged at 13,000 g for 20 min at 4°C. Aliquots of supernatant were frozen at –80°C, and a portion of these homogenates was used to determine total protein content (BCA method, Sigma Chemical). Proteins in the homogenates were separated on 8% or 10% polyacrylamide gels and transferred electrophoretically onto nitrocellulose paper. Protein blots of samples from incubated and non-incubated muscles were incubated with the appropriate dilution of commercially available...
antibodies against phospho-insulin receptor (IR)/IGF1R (Tyr1158/Tyr1162/Tyr1163) (Millipore), insulin receptor beta (IR-β), insulin receptor substrate 1 (IRS-1), phospho-IRS-1 (Ser207), phospho-Akt (Ser473), Akt, Akt substrate of 160kDa (AS160), phospho-AS160 (Thr642), c-Jun NH2-terminal kinase (SAPK/JNK), phospho-SAPK/JNK (Thr183/Tyr185), p38 mitogen-activated protein kinase (MAPK) and phospho-p38 MAPK (Thr180/Tyr182). Protein blots of samples from non-incubated muscles were also incubated with commercially available antibodies against GLUT-4, GLUT-1 (Santa Cruz Biotechnology), AMP-activated protein kinase (AMPK), phospho-AMPK Thr172, angiotensin-converting enzyme 1 (ACE1) (Abcam), ACE2 (Millipore), angiotensin II receptor type 1 (AT1R) (Santa Cruz Biotechnology), AT2R (Santa Cruz Biotechnology), MAS receptor (MasR) (Santa Cruz Biotechnology) and 4-hydroxynonenal (4-HNE) (Abcam). Subsequently, all blots were incubated with goat anti-rabbit, anti-mouse or anti-goat secondary antibodies conjugated with horseradish peroxidase (IgG-HRP). All antibodies, if not specified previously, were purchased from Cell Signaling Technology. Protein bands were visualized with enhanced chemiluminescence (PerkinElmer Life Sciences) on a C-Digit Blot Scanner (LI-COR Biotechnology, Lincoln, NE, USA) with Image Studio Software, version 3.1 for the quantitative analysis of band intensities.

Statistical analysis

All values are expressed as the means±S.E. Differences among groups were determined by one-way ANOVA with Tukey’s post hoc test. A two-way ANOVA was used to analyze the effects of two variables followed by Tukey’s post hoc test for multiple comparisons. Data lacking normal distribution and/or equal variance were mathematically transformed by the logarithm or square root to achieve normality and equal variance before one- or two-way ANOVA was being tested. Statistical analyses were performed using SigmaPlot 12.0 (Systat Software, San Jose, CA, USA). A value of $P<0.05$ was considered to be statistically significant.

Results

Effects of chronic ANGII infusion on body weight, tissue weight, food and water intake

The body weights, abdominal fat weights, heart weights and food and water intakes of the SHAM and ANGII-100 groups were comparable (Fig. 1 and Table 1). Compared to other groups, ANGII-500 infusion led to significant decreases in body weight (~15%) (Fig. 1A) and the abdominal fat weight-to-body weight ratio (~25%), as well as an increase in the heart weight-to-body weight ratio (17–20%) (Table 1). The amounts of daily food intake for the ANGII-500 group rapidly decreased ($P<0.05$) by 35% and continued at this level throughout the experiment (Fig. 1B), whereas the volume of water intake increased ($P<0.05$) (Fig. 1C).
Angiotensin II infusion and insulin resistance

Table 1 Final body weights, heart weights, fat weights, heart rate, fasting plasma glucose and insulin levels and serum triglycerides after SHAM and ANGII infusion at 100 and 500 ng/kg/min.

<table>
<thead>
<tr>
<th></th>
<th>SHAM</th>
<th>ANGII-100</th>
<th>ANGII-500</th>
</tr>
</thead>
<tbody>
<tr>
<td>BW (g)</td>
<td>420 ± 3.94</td>
<td>406 ± 6.90</td>
<td>351 ± 11.94*</td>
</tr>
<tr>
<td>HW (g)</td>
<td>1.55 ± 0.12</td>
<td>1.45 ± 0.18</td>
<td>1.42 ± 0.15*</td>
</tr>
<tr>
<td>HW/kg BW</td>
<td>3.69 ± 0.30</td>
<td>3.57 ± 0.46</td>
<td>4.05 ± 0.81*</td>
</tr>
<tr>
<td>FW (g)</td>
<td>17.1 ± 1.1</td>
<td>16.8 ± 1.0</td>
<td>10.3 ± 1.2*</td>
</tr>
<tr>
<td>FW/kg BW</td>
<td>40.7 ± 2.75</td>
<td>41.4 ± 3.16</td>
<td>29.3 ± 3.24*</td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>414 ± 12.9</td>
<td>429 ± 7.5</td>
<td>420 ± 12.8</td>
</tr>
<tr>
<td>Plasma glucose (mg/dL)</td>
<td>139 ± 11</td>
<td>135 ± 9</td>
<td>128 ± 15</td>
</tr>
<tr>
<td>Plasma insulin (µU/mL)</td>
<td>27.1 ± 5.0</td>
<td>23.9 ± 7.1</td>
<td>23.0 ± 6.1</td>
</tr>
<tr>
<td>Serum triglyceride (mg/dL)</td>
<td>32.2 ± 3.1</td>
<td>33.3 ± 4.9</td>
<td>51.3 ± 3.3*</td>
</tr>
</tbody>
</table>

Values are the means ± s.e. for 8–10 animals per group.
*P < 0.05 vs SHAM group; #P < 0.05 vs ANGII-100 group.

Blood pressure, heart rate, fasting plasma glucose and insulin and serum triglycerides

The systolic, diastolic and mean arterial blood pressures of the SHAM and ANGII-treated rats were determined before and after implantation of the osmotic minipump (Fig. 1D, E and F). The arterial pressures were relatively unchanged in the SHAM group, whereas ANGII-100 infusion gradually increased the systolic, diastolic and mean arterial blood pressures (P < 0.05) over the experimental period. When compared to ANGII-100, ANGII-500 significantly increased blood pressure to a greater extent. These results indicate that ANGII induced hypertensive conditions in a dose-dependent manner. No significant differences in heart rate, fasting plasma glucose and insulin levels among the groups were detected, whereas ANGII-500 infusion increased (P < 0.05) the serum triglyceride concentrations when compared with other groups (Table 1).

Glucose tolerance and insulin sensitivity after chronic ANGII infusion

The profiles of plasma glucose and insulin levels during OGTT are shown in Fig. 2. ANGII-100 infusion led to a significant increase in plasma insulin level at the 15-min time point with a trending increase in the area under the curve (AUC) for insulin (Fig. 2B and D), whereas ANGII-500 administration resulted in significant increases in plasma glucose levels at the 15-, 60- and 120-min time points (Fig. 2A) and glucose AUC (Fig. 2C) when compared to other groups. Despite the hyperglycemic response, however, insulin levels in the ANGII-500 group at the 15-, 30- and 120-min time points, and insulin AUC were significantly lower when compared with the ANGII-100 group (Fig. 2B). The glucose–insulin index (G–I index) is defined as the product of glucose AUC and insulin AUC and is inversely related to an increase in whole-body peripheral insulin sensitivity (Cortez et al. 1991). The G–I index of the ANGII-100 group was significantly higher than that in the SHAM group. Due to the opposing responses in terms of the plasma glucose and insulin levels, the G–I index in the ANGII-500 group was not changed when compared with that in SHAM.

Effect of chronic ANGII administration on soleus muscle glucose uptake

Skeletal muscle glucose uptakes in the absence and presence of insulin are depicted in Fig. 3A, and the

Figure 2 Glucose tolerance and insulin sensitivity after chronic ANGII infusion. Plasma glucose (A) and plasma insulin (B) responses during OGTT in rats receiving normal saline infusion (SHAM) and rats receiving ANGII infusion (ANGII-100 and ANGII-500). The glucose AUC (C), insulin AUC (D) and G–I index (E) were calculated to represent whole-body insulin sensitivity.

Values are the means ± s.e. for 8–10 animals/group. There was a significant main effect of time on the levels of plasma glucose (A) and insulin (B) in all groups. A significant main effect of ANGII treatment was observed. Post hoc analysis indicated *P < 0.05 vs SHAM group; #P < 0.05 vs ANGII-100 group.
insulin-induced glucose uptakes above basal levels are illustrated in Fig. 3B. When compared to the SHAM group, insulin-stimulated and insulin-mediated glucose uptakes in the muscles of ANGII-100-treated rats were significantly decreased by 33% and 39%, respectively. ANGII-500 infusion resulted in a significant increase in insulin-stimulated glucose uptake above the values of the ANGII-100 group (Fig. 3A). Insulin-mediated glucose uptake of the ANGII-500 group was comparable to that of SHAM but was significantly higher (~40%) than that of the ANGII-100 group (Fig. 3B).

### Insulin signaling elements, GLUT-1 and GLUT-4 abundance in skeletal muscle

To assess the impacts of chronic ANGII infusion on insulin signaling elements, the expression and phosphorylation levels of IR-β, IRS-1, Akt and AS160 were determined by immunoblot analysis in non-incubated soleus muscle. No significant changes in these proteins were observed among experimental groups (Fig. 4). Nevertheless, we found that GLUT-1 protein expression was comparable among groups, whereas ANGII-100 and ANGII-500 infusion brought about significant reductions in GLUT-4 protein abundance by 40% and 25%, respectively (Fig. 5A). To assess the ability of insulin to activate the signaling elements in the insulin signaling pathway, the phosphorylation and expression levels of IR-β, IRS-1, Akt and AS160 in the soleus strips incubated in the absence and presence of insulin were determined (Fig. 5B). There were no significant differences in the expression of IR-β, IRS-1, Akt and AS160 and the phosphorylation of IR-β among groups. Compared to SHAM, however, a significant increase in insulin-stimulated phosphorylation of IRS-1 Ser307 and decreases in insulin-stimulated phosphorylation of Akt Ser473 and AS160 Thr642 were observed in the ANGII-100 group. Interestingly, defects in the insulin signaling elements presented in the ANGII-100 group were not detected in the ANGII-500 group.

### Effect of ANGII treatment on ROS generation and the MAPK pathway

4-hydroxynonenal (4-HNE), a product of lipid peroxidation, has been implicated in the etiology of pathological alterations under oxidative stress and is considered to be a reliable index of ROS (Browning & Horton 2004, Wei et al. 2008). We found that the 4-HNE levels in the skeletal muscle of the ANGII-100 and ANGII-500 groups were 44% and 105% above that of the SHAM group, respectively (Fig. 6A). It appears that ANGII dose is
one factor that determines the degree of ROS generation. The expression and phosphorylation levels of p38 MAPK and SAPK/JNK were determined in soleus muscle strips to examine whether they were affected by chronic ANGII infusion. There were no significant changes in the protein expression. Compared with SHAM, ANGII-100 and ANGII-500 infusion enhanced ($P < 0.05$) the phosphorylation levels of p38 MAPK by 3- to 4-fold, whereas ANGII-500 also increased SAPK/JNK by 21% (Fig. 6B). To investigate whether these MAPKs were associated with alterations in insulin-stimulated glucose transport activity, the expression and phosphorylation levels of these MAPKs were assessed in muscle strips incubated in the absence or presence of insulin. We found that the patterns of

Figure 5
GLUT-1 and GLUT-4 abundance and insulin signaling elements in skeletal muscle. GLUT-1 and GLUT-4 protein expression (A) in non-incubated soleus muscle that were obtained from rats receiving normal saline infusion (SHAM) and rats receiving ANGII infusion (ANGII-100 and ANGII-500). Insulin-induced expression and phosphorylation of insulin signaling elements in incubated soleus muscles in the absence or the presence of insulin (2 mU/mL) (B). Proteins were determined by immunoblot analysis and were normalized to GAPDH. Data are presented as the fold change over the SHAM. Representative bands from the C-Digit Blot Scanner are displayed at the top of the figure. Values are the means ± s.e. for 6–8 animals/group. There was a significant main effect of insulin on phosphorylation of insulin signaling elements (B). A significant main effect of ANGII treatment was observed. Post hoc analysis indicated *$P < 0.05$ vs SHAM group; **$P < 0.05$ vs ANGII-100 group.
changes for p38 MAPK and SAPK/JNK observed in the non-incubated and incubated muscle strips were similar, and insulin did not enhance the levels of these MAPKs (Fig. 6C).

Expression of AMPK, AT1R, AT2R, ACE1, ACE2 and MasR in skeletal muscle

Increased glucose transport activity can be mediated by other molecules, such as AMPK and the ACE2/ANG(1–7)/MasR axis, which are independent of insulin (Ruderman et al. 2013, Echeverria-Rodriguez et al. 2014). We found that a reduction in the phosphorylation levels of AMPK Thr172 was observed only in the ANGII-100 group (Fig. 7A). ANGII-100 and ANGII-500 increased ACE2 protein expression above the SHAM level by 31% and 85%, respectively (Fig. 7C). Although ANGII-100 infusion did not affect the expression of MasR protein, ANGII-500 significantly enhanced (P<0.05) MasR by 68% (Fig. 7C). We also showed that the expression of proteins in the classic RAS including AT1R, AT2R and ACE1 was not different among experimental groups (Fig. 7B).

Discussion

The present study demonstrated that chronic infusion with ANGII-100 induced skeletal muscle insulin resistance, which was associated with decreases in total GLUT-4 abundance, phosphorylation of AMPK Thr172 and insulin-stimulated phosphorylation of Akt Ser473 and AS160 Thr642 with increases in oxidative stress markers, phosphorylation of p38 MAPK Thr180/Tyr182 and insulin-stimulated phosphorylation of IRS-1 Ser307 (negatively regulates IRS function). Importantly, the main finding of this study provided novel information that not only did chronic ANGII-500 infusion fail to aggravate insulin resistance as anticipated, but insulin-stimulated skeletal muscle glucose transport activity of the ANGII-500 group was comparable to the level of the SHAM group. Intriguingly, insulin action on glucose transport activity,
the phosphorylation of IRS-1 Ser^{307}, Akt Ser^{473} and AS160 Thr^{642} and the phosphorylation of AMPK Thr^{172} in skeletal muscle of the ANGII-500 and SHAM groups was comparable, whereas ANGII-500 additionally increased ACE2 and MasR protein expression above SHAM group levels. At the whole-body level, rats treated with ANGII-100 were characterized by phenotypic features of non-obese metabolic syndrome, whereas ANGII-500-treated rats exhibited diabetes-like symptoms.

Rodents infused with a broad range of ANGII concentrations (10–1440 ng/kg/min) via implantable osmotic minipumps have been used as a valuable experimental model to investigate the pathology of hypertension and associated conditions (for a review, see Qin (2008)). The severity of hypertension, diabetes and cardiovascular dysfunction has been reportedly associated with plasma ANGII levels (Catt et al. 1969, Staroukine et al. 1984, Nicola et al. 2001). Chronic ANGII infusion at 100 ng/kg/min, which has been most often used, led to several features of insulin resistance syndrome such as hypertension, hypertriglyceridemia and impaired insulin sensitivity (Ran et al. 2004, 2005). Despite this, it remains unknown how insulin action on skeletal muscle glucose transport is affected when plasma ANGII levels rise to a higher pressor dose, a condition observed in individuals with severe hypertension and impaired cardiac function. In fact, only two studies have investigated the causal role of ANGII infusion in the development of skeletal muscle insulin resistance. The investigators chronically infused ANGII at 100 and 200 ng/kg/min (Ogihara et al. 2002, Lastra et al. 2013), and their results were contradictory. Impaired insulin-stimulated glucose transport activity
of skeletal muscle in rats was associated with (1) enhanced insulin signaling elements, including tyrosine phosphorylation of IRS-1 and IRS-2 and the activation of PI3-K and Akt after chronic intravenous ANGII infusion at 100 ng/kg/min (Ogihara et al. 2002) and (2) diminished phosphorylation of Akt and AS160 after chronic subcutaneous infusion with ANGII at 200 ng/kg/min (Lastra et al. 2013). The present study demonstrates that rats that received chronic subcutaneous ANGII infusion at 100 ng/kg/min exhibited gradually elevated blood pressure and insulin resistance of skeletal muscle glucose transport activity with multiple post-receptor defects, including increased IRS-1 Ser307 phosphorylation, decreased phosphorylation of Akt Ser473 and AS160 Thr642 and diminished GLUT-4 protein abundance (Fig. 8A). Thus, our results are consistent with those reported by Lastra and coworkers (Lastra et al. 2013), and we speculate that the ANGII dose and route of administration may explain the paradoxical observations between our study and Ogihara and coworkers (Ogihara et al. 2002).

Reactive oxygen species (ROS) have been implicated as a link between ANGII and insulin resistance (Henriksen et al. 2011). Previous studies in cultured L6 myotubes revealed that ANGII activated ROS and impaired insulin signaling molecules (Wei et al. 2006, 2008). Moreover, skeletal muscle insulin resistance in transgenic TG(mRen2)27 (Sloniger et al. 2005) and hypertensive Dahl salt-sensitive rats (Zhou et al. 2015) was associated with significant increases in oxidative stress and elevated tissue ANGII levels. It has been demonstrated that the mitogen-activated protein kinase (MAPK) pathway, in particular p38 MAPK and SAPK/JNK, has an important role in ROS-induced insulin resistance, as ROS activates these kinases, which negatively modulate insulin-stimulated glucose transport activity (Kim et al. 2006, Archuleta et al. 2009, Vichaiwong et al. 2009, Santos et al. 2012). The present study demonstrated that infusion with ANGII-100 and ANGII-500 enhanced ROS formation and MAPK activity in the soleus muscle in a dose-dependent manner and increased ROS formation and MAPK activity in the ANGII-100 group was associated with skeletal muscle insulin resistance. Nevertheless, unlike the findings in the ANGII-100 group, further increases in ROS generation and MAPK activity in the ANGII-500 group did not compromise insulin action on glucose transport activity. Unexpectedly, we found that ANGII-500 infusion led to normalization of the insulin-stimulated phosphorylation of IRS-1 Ser307, Akt Ser473, AS160 Thr642 and skeletal muscle glucose transport activity to the levels of the SHAM group.

There are a few possible mechanisms that may explain our findings from the ANGII-500 group. First, it is well documented that a reduction in caloric intake, such as a moderate degree of calorie restriction, can enhance glucose uptake and insulin signaling elements in rat skeletal muscle (Park et al. 2005, Speakman & Mitchell 2011, Prasannarong et al. 2012). A series of experiments have shown that phosphorylation of Akt, especially on Akt2, is essential for the favorable effect of calorie restriction on glucose uptake (Carrie E McCurdy et al. 2003, McCurdy & Cartee 2005, Wang et al. 2016). In this study, the average food intake in the ANGII-500 group was significantly lower than other groups by 25–35%.

Figure 8
Proposed mechanisms underlying the effects of ANGII on the skeletal muscle glucose transport system. ANGII-100 activates NADPH oxidase to generate reactive oxygen species (ROS) and enhances MAPK, resulting in diminished insulin-stimulated insulin signaling and glucose transport activity (A). ANGII-500 induces a reduction in caloric intake and activates AMPK phosphorylation. Excessive ANGII enhances protein expression in the ACE2/ANG(1–7)/MasR axis (B).
Thus, our findings are consistent with a notion that reduced caloric intake could be a contributing factor that enhanced skeletal muscle insulin action and signaling in the ANGII-500 group. Second, it has been shown that ANGII inactivated the activity of AMPK (Yoshida et al. 2009, Deji et al. 2012), a sensor of cellular energy status that can stimulate GLUT-4 translocation to the plasma membrane independent of insulin. Our data also showed that phosphorylation of AMPK was indeed inhibited in the ANGII-100 group, and we found that AMPK Thr172 in the skeletal muscle of the ANGII-500 group was maintained to the level of the SHAM group. As the AMPK system can be altered when cellular energy homeostasis is disturbed, such as the disturbance occurring during calorie restriction (Hardie 2003, Towler & Hardie 2007, Wang et al. 2012), we speculate that intact levels of AMPK Thr172 may be essential to maintain glucose transport activity. Third, evidence for the counter-regulatory role of the ACE2/ANG(1–7)/MasR axis against the action of ANGII via the ACE/ANGII/AT1R axis is emerging (Giani et al. 2009, Echeverria-Rodriguez et al. 2014, Santos & Andrade 2014). The essential role of ACE2, which cleaves ANGII into ANG(1–7), as a negative regulator of the RAS in several disease conditions has been recognized (Fernandes et al. 2010, Song et al. 2013, Takeda et al. 2013). Studies have shown that activity of the ACE2/ANG(1–7)/MasR axis that counteracts ANGII signaling occurs via a MasR-dependent mechanism. For instance, a selective antagonist of MasR completely prevented the positive effects of ANGII on insulin-mediated glucose transport (Prasannarong et al. 2012a). Importantly, ACE2 and ANG(1–7) concentrations were increased when AT1R was inhibited (Zimmerman et al. 2014). Thus, we hypothesized that ANGII-500 administration provided excessive available ANGII, which became a substrate for the ACE2/ANG(1–7)/MasR axis (Fig. 8B). Consequently, the enhanced ACE2 and MasR protein expression contributed to the normalization of insulin action and signaling. Importantly, the present study has provided new information that the expression of proteins in the classical RAS including AT1R, AT2R and ACE1 in skeletal muscle was not affected by chronic ANGII infusion.

The impact of ANGII on GLUT-4 protein expression has been addressed in a limited number of studies. An earlier report found that ANGII-100 infusion induced skeletal muscle insulin resistance without affecting total GLUT-4 content (Ogihara et al. 2002). In contrast, several studies showed that treatment with an ACE or AT1R antagonist increased GLUT-4 protein expression and attenuated insulin resistance in rat skeletal muscle (Jacob et al. 1996, Henriksen et al. 2001). Additionally, GLUT-4 protein expression and its transcriptional factors were reduced in the skeletal muscle of ACE2-knockout mice (Takeda et al. 2013). In the present study, we found that chronic ANGII infusion resulted in a significant reduction in total GLUT-4 abundance. Thus, our findings provide evidence to support the concept that ANGII can negatively modulate GLUT-4 protein expression.

A further novel finding from the present study is the observation that rats chronically infused with ANGII-100 and ANGII-500 exhibited multiple differences in metabolic features. In addition to hypertension and skeletal muscle insulin resistance, rats treated with ANGII-100 developed impaired glucose tolerance as indicated by the higher G–I index. Glucose intolerance in these rats occurred without significant changes in energy intake, abdominal fat weight and body weight or serum triglyceride levels when compared to SHAM animals. Thus, our observations suggest that chronic ANGII-100 infusion induced a number of phenotypic characteristics representing non-obese insulin resistance syndrome. On the other hand, ANGII-500-treated rats exhibited lower energy intake, less abdominal fat accumulation and body weight, an aggravated degree of hypertension and hypertriglyceridemia. Importantly, compensatory hyperinsulinemia did not occur, even when hyperglycemia was observed during OGTT. Our findings confirmed the results demonstrated by Müller and coworkers that a high dose of chronic ANGII infusion brought about hyperglycemia and hyperinsulinemia during an oral glucose tolerance test (Müller et al. 2007). Because ANGII was reported to participate in the development of pancreatic fibrosis associated with pancreatic cell apoptosis (Carlsson et al. 1998, Osborn et al. 2011), our results are consistent with the notion that chronic ANGII-500 administration impaired beta cell function, which led to the conditions mimicking type 1 diabetes.

It should be noted that lack of plasma ANGII measurements due to technical problems is a limitation to this study. Nevertheless, other studies employing the same osmotic minipump model have reported that plasma ANGII concentrations in rats infused with ANGII at 100ng/kg/min and 500ng/kg/min were 2-fold and 4- to 6-fold higher than the control levels, respectively (Cassis et al. 1998, Huang et al. 2010). Our observation that hypertensive conditions were additionally aggravated in the ANGII-500 group also implies higher ANGII levels in the ANGII-500 group.
Conclusion

The present investigation demonstrates for the first time that ANGII at a commonly used dose (ANGII-100) and at a higher pressor dose (ANGII-500) differentially modulates metabolic features. In skeletal muscle, ANGII-100 induced skeletal muscle insulin resistance and impaired the insulin signaling pathway, whereas ANGII-500 normalized insulin-stimulated skeletal muscle glucose transport activity and other signaling molecules to SHAM levels. At the whole-body level, ANGII-100-treated rats were characterized by certain phenotypic manifestations that described non-obese insulin resistance syndrome, whereas ANGII-500-treated rats displayed diabetes-like features. Therefore, our findings support the notion that ANGII is one of the contributing factors in the development of insulin resistance and diabetes in hypertensive patients. Additionally, the evidence presented in this study suggests that ANGII doses should be cautiously taken into consideration when ANGII is used to investigate the pathology of diseases in animal models.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by grants from the Faculty of Science, Mahidol University, and The Thailand Research Fund (TRF) through the Royal Golden Jubilee (RGJ) Ph.D. Program (Grant PHD/0228/2552).

References


Downloaded from Bioscientifica.com at 12/15/2018 09:07:13PM via free access

Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM & Stump CS 2008


Received in final form 13 January 2017
Accepted 17 January 2017
Accepted Preprint published online 17 January 2017